AFT Pharmaceuticals to Release FY2025 Results on May 22

An update from AFT Pharmaceuticals Ltd. ( (AU:AFP) ) is now available.

AFT Pharmaceuticals has announced it will release its full-year FY2025 results on May 22, 2025. The release will be followed by a management presentation via webinar, with materials available on the company’s website and stock exchange platforms. This announcement is significant for stakeholders as it provides insights into the company’s financial performance and strategic direction, potentially impacting its market positioning and investor relations.

More about AFT Pharmaceuticals Ltd.

AFT Pharmaceuticals is a New Zealand-based multinational pharmaceutical company that develops, markets, and distributes a wide range of pharmaceutical products across various therapeutic categories. The company operates in major pharmaceutical distribution channels, including over the counter, prescription, and hospital, with a product portfolio that includes proprietary, in-licensed, patented, branded, and generic drugs. AFT Pharmaceuticals focuses on markets in Australia, New Zealand, Singapore, Malaysia, Hong Kong, USA, Canada, EU excluding Ireland and UK, and licenses its products to over 125 countries worldwide.

YTD Price Performance: -8.63%

Average Trading Volume: 1,780

Technical Sentiment Signal: Buy

Current Market Cap: A$257.9M

For an in-depth examination of AFP stock, go to TipRanks’ Stock Analysis page.